Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies-Reference-Cited by-同舟云学术

Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies

Published:2020-04-30 Issue:4 Volume:17 Page:e1003100
ISSN:1549-1676
Container-title:PLOS Medicine
language:en
Short-container-title:PLoS Med

Author:

Jarvis Helen^ORCID,Craig Dawn^ORCID,Barker Robert^ORCID,Spiers Gemma^ORCID,Stow Daniel^ORCID,Anstee Quentin M.,Hanratty Barbara^ORCID

Funder

National Institute for Health Research

Publisher

Public Library of Science (PLoS)

Subject

General Medicine

Reference55 articles.

1. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes;ZM Younossi;Hepatology,2016

2. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease;European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO);J Hepatol,2016

3. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up;M Ekstedt;Hepatology,2015

4. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD;H Hagström;J Hepatol,2017

5. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease;P Angulo;Gastroenterology,2013

Cited by 256 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diabetes as a risk factor for MASH progression;Diabetes Research and Clinical Practice;2024-11

2. Natural history and progression of metabolic dysfunction-associated steatotic liver disease;The Lancet Gastroenterology & Hepatology;2024-10

3. The magnitude and factors associated with chronic liver disease in Ethiopia: a cross- sectional study;2024-09-02

4. Protective effects of Nogo-B deficiency in NAFLD mice and its multiomics analysis of gut microbiology and metabolism;Genes & Nutrition;2024-08-24

5. Application of PPAR Ligands and Nanoparticle Technology in Metabolic Steatohepatitis Treatment;Biomedicines;2024-08-16